Renovaro Biosciences (RENB) Form 3 RENOVARO BIOSCIENCES / Ole Abildgaard ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Abildgaard Ole

(Last) (First) (Middle)

VEDBAEK STRANDVEJ 506

(Street)

VEDBAEK G7 2970

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/01/2023

3. Issuer Name and Ticker or Trading Symbol
RENOVARO BIOSCIENCES INC. [ RENB ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	3,462,292	I	By Paseco ApS
Common Stock	5,000	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series A Convertible Preferred Stock	08/01/2023(1)	(1)	Common Stock	3,436,190	0(1)	I	By Paseco ApS(2)
Warrants (right to buy)	03/29/2023	03/29/2028	Common Stock	125,000	1.14	I	By Paseco ApS(2)
Warrants (right to buy)	06/26/2023	06/26/2028	Common Stock	1,415,870	0.53	I	By Paseco ApS(2)
Warrants (right to buy)	08/01/2023	08/01/2028	Common Stock	1,718,095	0.65	I	By Paseco ApS(2)

Explanation of Responses:

1. The Series A Convertible Preferred Stock ("Preferred Stock") is convertible into Common Stock on a one-for-ten basis and has no expiration date

2. Ole Abildgaard, as Chief Executive Officer and sole shareholder of Paseco ApS, beneficially owns the reported securities indirectly, but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein.

	/s/ Ole Abildgaard	10/06/2023
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.